NewsBenzingaTango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026 Tango Therapeutics To Present Updated Data From Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib Or Zoldonrasib In Patients With MTAPdel/RASmut Metastatic PDAC And NSCLC At ESMO Congress 2026 Benzinga 2026.10.16 11:05 (GMT+0) Open on Benzinga Other news Metis to End Support for Stargate, LayerZero Services to Cease on October 30 Domino's Pizza Sees Lower FCF Margins, But It's Worth One-Third More - What's the Best DPZ Play? ‘The Idea That You Need to Reserve Things for Humans May Sound Bizarre, But We Will Get There’: Bill Gates Says Al Is Bigger Than Internet Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma M&T Bank Q3 2026 Earnings Call Transcript Reported October 15, 'DeepSeek offers user refunds after suffering another major outage' - SCMP
‘The Idea That You Need to Reserve Things for Humans May Sound Bizarre, But We Will Get There’: Bill Gates Says Al Is Bigger Than Internet
Committee For Medicinal Products For Human Use Recommends Approval Of Indication Extension Of Johnson & Johnson's TALVEY To Treat Adults With Relapsed Or Refractory Multiple Myeloma
